Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation

This study has been completed.
Cystic Fibrosis Foundation Therapeutics
Information provided by (Responsible Party):
James F. Chmiel, University Hospital Case Medical Center Identifier:
First received: March 14, 2011
Last updated: May 28, 2015
Last verified: May 2015
The purpose of this study to investigate the effect of sulforaphane from macerated broccoli sprouts in humans and to evaluate less invasive methods of assessing potential anti-inflammatory drugs in CF.

Condition Intervention
Cystic Fibrosis
Dietary Supplement: Broccoli sprouts

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: Evaluation of the Effect of Sulforaphane in Broccoli Sprouts on Nrf2 Activation, Measures of Oxidative Stress, and Neutrophil Migration to Mucosal Surfaces in Healthy and CF Subjects

Resource links provided by NLM:

Further study details as provided by University Hospitals Cleveland Medical Center:

Primary Outcome Measures:
  • Nrf2 activation in nasal epithelial cells [ Time Frame: Days 3 and 8 ] [ Designated as safety issue: No ]
    Nrf-2 will be determined by western blot analysis from nasal epithelial cells obtained by curretage.

Secondary Outcome Measures:
  • Measures of lipid peroxidation in nasal epithelial cells [ Time Frame: Days 3 and 8 ] [ Designated as safety issue: No ]
    Products of lipid peroxidation will be determined by western blot analysis on nasal epithelial cells obtained by curretage.

  • Measures of glutathione from blood lymphocytes [ Time Frame: Days 3 and 8 ] [ Designated as safety issue: No ]
    Blood will be withdrawn from the subjects and monocytic cells will be obtained for analysis of intracellular glutathione.

  • Measures of oxidative stress in urine [ Time Frame: Days 3 and 8 ] [ Designated as safety issue: No ]
    Urine will be obtained on days 3 and 8 for quantification of F2-isoprostane and bromotyrisine.

  • Measure of neutrophil migration into the gingival crevices [ Time Frame: Days 1, 2, 3, 6, 7, 8 ] [ Designated as safety issue: No ]
    Patients will perform mouthwashes with normal saline. Neutrophil counts will be performed on fresh samples. Acradine orange will be added to the saline rinses and neutrophils will be counted under the microscope

Enrollment: 15
Study Start Date: April 2011
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Broccoli Sprouts
Healthy volunteers and subjects with cystic fibrosis
Dietary Supplement: Broccoli sprouts
Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
Other Name: sulforaphane

Detailed Description:

The hypothesis to be tested is that sulforaphane consumed from macerated broccoli sprouts will activate Nrf2, reduce oxidative metabolites and reduce neutrophils in the oral mucosa after 5 days of therapy in healthy volunteers and CF subjects.

The study requires 6 brief outpatient visits over 8 days. Study procedures include medical history, height, weight, vital signs, blood and urine collection, nasal curettage, saline mouthwash, and ingestion of broccoli sprouts (100 gm of 3 to 5 day old raw broccoli sprouts once daily for 5 consecutive days).


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers and patients with cystic fibrosis ≥ 18 < 50 years of age
  • Healthy volunteers must be in general good health as determined by a medical history
  • CF subjects must have a documented diagnosis of CF (positive sweat chloride ≥ 60 mEq/liter, by pilocarpine iontophoresis) and/or a genotype with two identifiable mutations consistent with CF accompanied by one or more clinical features with the CF) phenotype
  • CF subjects must have a baseline FEV1 percent predicted > 50% (in the last year, obtained from medical record)
  • CF subjects must be clinically stable: free of any acute illness for > 14 days CF subjects must not have been prescribed any new systemic antibiotics for the 14 days prior to enrollment
  • Ability to provide written informed consent
  • Ability to adhere to the protocol

Exclusion Criteria:

  • Use of NSAIDS (e.g., ibuprofen) or corticosteroids including inhaled steroids for the 4 weeks prior to enrollment
  • Active gingival disease (active tooth or gum disease)
  • History of nephrolithiasis or cholelithiasis
  • Allergy to broccoli
  • Any chronic condition that compromises the participant as determined by medical history
  • Pregnancy
  • Inability to tolerate the study procedures
  • CF subjects: Infected with B. cepacia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01315665

United States, Ohio
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States, 44106
Sponsors and Collaborators
University Hospitals Cleveland Medical Center
Cystic Fibrosis Foundation Therapeutics
Principal Investigator: James F. Chmiel, MD, MPH Rainbow Babies and Children's Hospital
  More Information


Responsible Party: James F. Chmiel, Associate Professor of Pediatrics, University Hospital Case Medical Center Identifier: NCT01315665     History of Changes
Other Study ID Numbers: UHCMC-CFRC-2011-01 
Study First Received: March 14, 2011
Last Updated: May 28, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by University Hospitals Cleveland Medical Center:
broccoli sprouts
Nrf2 activation
cystic fibrosis
healthy volunteers

Additional relevant MeSH terms:
Cystic Fibrosis
Pathologic Processes
Pancreatic Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Anticarcinogenic Agents
Protective Agents
Physiological Effects of Drugs
Antineoplastic Agents processed this record on December 07, 2016